Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Amifampridine Phosphate
Therapeutic Area : Immunology
Study Phase : Approved
Sponsor : Catalyst Pharmaceuticals
Deal Size : Not Applicable
Deal Type : Not Applicable
Catalyst Pharma Sub-Licensee Gets Approval For FIRDAPSE® in Japan
Details : Firdapse (amifampridine) is an oral, nonspecific, voltage-dependent, potassium channel blocker that received approval to treat Lambert-Eaton myasthenic syndrome in Japan.
Brand Name : Firdapse
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 24, 2024
Lead Product(s) : Amifampridine Phosphate
Therapeutic Area : Immunology
Highest Development Status : Approved
Sponsor : Catalyst Pharmaceuticals
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?